Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Johnson & Johnson

www.jnj.com

Latest From Johnson & Johnson

Teva Seeks Global Resolution Of Opioid Litigation As Bellwether Trial Is Halted

Teva and three distributors settle with two plaintiffs; PBMs are defendants in next case as Teva also reaches an agreement in principal with four attorneys general for global settlement framework. 

Legal Issues Advertising, Marketing & Sales

J&J's Spravato Set For EU Launches Soon

If the nasal spray is approved by the European Commission, seven months after getting the green light in the US, Spravato will offer the first new mechanism of action in 30 years to treat major depressive disorder.
Neurology Drug Review

Opioid Trial Preview: The Claims, Defenses, And Last-Minute Maneuvers

Trial opens after settlement proposals by three distributors, Teva and J&J fail to gain support of cities and counties. Distributors want to call former FDA Commissioner Kessler to testify over plaintiffs' objections. Judge rules plaintiffs cannot seek future damages.

Legal Issues Advertising, Marketing & Sales

J&J Starts First Baby Powder Recall Linked To Asbestos Finding

Recall announcement doesn't mention litigation J&JU faces in multiple states alleging use of Johnson's Baby Powder causes cancer due from talc in formulation. But firm's sensitivity to consumer complaints or adverse event reports linked to brand is clear with talc-related litigation as backdrop.

OTC Drugs Cosmetic Ingredients
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register